An Analysis of Alnylam Pharmaceuticals Inc. (ALNY)’s Potential Price Growth

0
1
MDNA
MDNA

Alnylam Pharmaceuticals Inc.’s recent filing unveils that its Director SHARP PHILLIP A unloaded Company’s shares for reported $7.76 million on Aug 15. In the deal valued at $230.49 per share,33,670 shares were sold. As a result of this transaction, SHARP PHILLIP A now holds 0 shares worth roughly $ 0.0.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, Tanguler Tolga sold 1,841 shares, generating $401,630 in total proceeds. Upon selling the shares at $218.16, the EVP, Chief Commercial Officer now owns 0 shares.

Before that, Tanguler Tolga sold 1,754 shares. Alnylam Pharmaceuticals Inc. shares valued at $368,340 were divested by the EVP, Chief Commercial Officer at a price of $210.00 per share. As a result of the transaction, Tanguler Tolga now holds 3,629 shares, worth roughly $0.76 million.

A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid July with a ‘”a Neutral”‘ rating. Guggenheim also remained covering ALNY and has decreased its forecast on June 27, 2022 with a “Neutral” recommendation from previously “Buy” rating. William Blair started covering the stock on June 07, 2022. It rated ALNY as “an Outperform”.

Price Performance Review of ALNY

On Friday, Alnylam Pharmaceuticals Inc. [NASDAQ:ALNY] saw its stock fall -3.42% to $208.34. Over the last five days, the stock has gained 1.87%. Alnylam Pharmaceuticals Inc. shares have risen nearly 22.86% since the year began. Nevertheless, the stocks have risen 12.28% over the past one year. While a 52-week high of $236.80 was reached on 08/12/22, a 52-week low of $117.58 was recorded on 05/12/22. SMA at 50 days reached $203.57, while 200 days put it at $167.28. A total of 0.75 million shares were traded, compared to the trading of 0.66 million shares in the previous session.

Levels Of Support And Resistance For ALNY Stock

The 24-hour chart illustrates a support level at 202.55, which if violated will result in even more drops to 196.76. On the upside, there is a resistance level at 214.77. A further resistance level may holdings at 221.20. The Relative Strength Index (RSI) on the 14-day chart is 55.28, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 10.61, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 40.06%. Stochastics %K at 76.86% indicates the stock is a holding.

How much short interest is there in Alnylam Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc. stocks on Jul 14, 2022, growing by 0.25 million shares to a total of 4.99 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 4.74 million shares. There was a rise of 5.01%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.86% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.59.

Alnylam Pharmaceuticals Inc. [ALNY] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 13,882,737 shares, or roughly 11.57% of the outstanding ALNY shares. In other words, the investor’s shares have fallen by -1,653,397 from its previous 13-F filing of 15536134.0. Additionally, Capital Research & Management Co increased 24.54% of its stake after which the total value it holdings stand at $2,565,406,084, while The Vanguard Group, Inc. added 1.92% of its stake to hold $2.16 billion in the firm. Over the last quarter, Baillie Gifford & Co. sold -453,676 shares of Alnylam Pharmaceuticals Inc., while T. Rowe Price Associates, Inc. sold 202,916 shares. At present, Wellington Management Co. LLP is holding 5,812,870 shares valued at $1.16 billion. BlackRock Fund Advisors owned 5,390,995 shares of the company at the time of its most recent 13F filing, worth $1.08 billion.

According to FactSet, Alnylam Pharmaceuticals Inc.’s share price will average $241.11 in the next year, based on opinions of analysts polled by the firm. This is up nearly 13.34 percent from its previous closing price of $215.72. Analysts expect Alnylam Pharmaceuticals Inc. stock to reach the higher price of $415.00, while the lowest price estimate is $142.00. However, 25 analysts have rated ALNY stock as an Overweight in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here